Roche: Analyst consensus compiled by the company shows that biosimilar drugs are expected to create a sales gap of 6.2 billion Swiss francs by 2030.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.